Strategic alliance Leverage OncoResponse’s broad strategic alliance with MD Anderson Cancer Center and their B-cell discovery platform to position joint development or co-investment opportunities in tumor microenvironment therapeutics, particularly for OR2805 and related candidates.

Clinical-stage traction Target pharma or biotech buyers seeking late-stage oncology immunotherapy assets or collaborators for Phase 1/2 readouts, emphasizing OR2805 clinical studies and the potential for rapid translation to clinical development.

Immuno-oncology focus Prioritize opportunities with immune cell–targeting antibodies and microenvironment modulation, aligning with OncoResponse’s expertise in elite responder-derived antibodies to differentiate from competition.

Funding signals Capitalize on CPRIT grant support and recent fundraising momentum as proof points for financial stability and government/private funding readiness, offering partners confidence in long-term collaboration viability.

Geographic reach Engage potential collaborators and licensees across Texas, Seattle, and broader U.S. markets, presenting a capable, multi-site development and business footprint to support parallel global trials and regulatory strategies.